Case reportSurprising results of a supportive integrated therapy in myelofibrosis

- Weight loss and cachexia greatly affect prognosis in myelofibrosis patients.
- A multitargeted approach effectively counteracted cachexia in a patient with myelofibrosis.
- The combinatorial approach resulted in the remission of all myelofibrosis-related symptoms.
- Our results support the role of inflammation in the pathogenesis of myelofibrosis symptoms.

ObjectivesMyelofibrosis (MF) is characterized by shortened survival and a greatly compromised quality of life. Weight loss and cachexia seem to be the most important factors influencing survival in patients with MF. The aim of this study was to assess the efficacy of an integrated supportive therapy in improving cachexia and MF-related symptoms.MethodsWe reported on a case of a patient with MF who presented with weight loss and cachexia associated with severe anemia, fatigue, fever, and bone pain. The circulating levels of inflammatory, oxidative stress parameters, hepcidin, and erythropoietin were evaluated and were above normal ranges. The patient was treated with a multitargeted approach specifically developed for cachexia including oral l-carnitine, celecoxib, curcumin, lactoferrin, and subcutaneous recombinant human erythropoietin (EPO)-α.ResultsSurprisingly, after 1 y, cachexia features improved, all MF symptoms were in remission, and inflammatory and oxidative stress parameters, hepcidin, and EPO were reduced.ConclusionsBecause our protocol was targeted at inflammation and the metabolic state, its effectiveness may emphasize the role of inflammation in the pathogenesis of MF symptoms and demonstrates a need for the study of new integrated therapeutic strategies.